Contineum Therapeutics (CTNM) 2025 Conference May 20, 2025 08:30 AM ET Speaker0 The biggest issue with this compound was it had an off target toxicity that, at that time, back in 2011, '20 '12 time frame, was not screened. So this BCEP issue off target led to polycystitis. Trial was discontinued. It's awesome. So that was probably the biggest issue there. But the data that was was those the start of those data along with BMS two seventy eight, which now called Edmilperant. I'll screw up the the pronunciatio ...